CURRICULUM VITAE (As of Feb 2016)

Jin Wang
Address: Dept. Pharmaceutical Sciences, College of Pharmacy
University of Oklahoma Health Sciences Center
1110 N. Stonewall Ave. CPB350
Oklahoma City, OK 73117-1200
Phone: +1-(405) 271-6593
E-mail: jin-wang-1@ouhsc.edu

EDUCATION

The University of Tennessee Health Science Center (UTHSC) Aug. 2010 – Aug. 2015
Ph.D. in Pharmaceutical Sciences

Sun Yat-Sen University (SYSU), P. R. China Sep. 2005-Jul. 2009
B. S. in Pharmacy, graduated with honor

PROFESSIONAL EXPERIENCE

Postdoctoral Research Fellow Aug.2015 – present
University of Oklahoma Health Science Center
Anti-cancer drug system pharmacology and pharmacodynamics/ pharmacokinetics modeling.

Graduate Teaching and Research Assistant (UTHSC) Aug. 2010 – Aug. 2015
Explore and evaluate new combination strategies to overcome acquired resistance to Braf inhibition in cellular and rodent melanoma models with mechanism study.
Hit compound identification, assay development, target validation and *in vivo* anti-tumor efficacy evaluation of novel small molecule survivin inhibitors.
Profile the physicochemical, metabolic and mouse or rat pharmacokinetic properties of novel tubulin or survivin inhibitors and vitamin D_3 derivatives.
Author research articles and grant applications with academic supervisor.
Lead group recitation of Pharmaceutics (PHSC 123) and Medicinal Chemistry (MEDC 112/122) courses for PharmD students.

Research Assistant (SYSU) Jul. 2008 – May. 2010
Develop novel compaction techniques with pellet-containing granules for sustained release tablets. Profile the drug release pattern from sustained release tablets or micro emulsion dosage form.
Evaluate the pharmacokinetic properties of sustained release dosages of doxycycline using rodent and canine models.

HONORS AND AWARDS

Alma and Hal Reagan Fellowship ($21,000 fellowship plus $1,000 travel/supplies, successful competitive renewal for an additional year of award (maximum allowable is two years), 10/2013-9/2014 from UTHSC
First Prize of Excellent Student Scholarship (SYSU, 2005-2007)
Honor of Excellent Student Leadership (SYSU, 2005-2007)

SOCIETY MEMBERSHIP

American Association for Cancer Research (AACR, 2012-present)

PEER-REVIEWED JOURNAL ARTICLES

1.Banerjee S, **Wang J**, Pfeffer S, Ma D, Pfeffer LM, Patil SA, Li W, Miller DD. "Design, Synthesis and Biological Evaluation of Novel 5H-Chromenopyridines as Potential Anti-Cancer Agents". *Molecules*. 2015, 20(9):17152-65.
2. Masoud GN, **Wang J**, Chen J, Miller D, Li W. "Design, synthesis and biological evaluation of novel HIF1α Inhibitors". *Anticancer Research.* 2015, 35(7): 3849-3859.
3. Hwang D, **Wang J**, Li W, Miller DD. "Structural optimization of indole derivatives acting at colchicine binding site as potential anticancer agents". *ACS Med. Chem. Lett.* 2015, 6(9): 993-997.

4. Xiao M, **Wang J**, Lu Y, Miller DD, Li W. "Design, synthesis and structure-activity relationship studies of novel survivin inhibitors with potent anti-proliferative properties". *PLos One*, 2015, 10(6):e0129807.

5. Slominski AT, Li W, Kim T, Semak I, **Wang J**, Zjawiony JK, Tuckey RC. "Novel activities of CYP11A1 and their potential physiological significance". *J Steroid Biochem Mol Biol*. 2015, 151: 25-37.

6. Lu Y, Chen J, **Wang J**, Li CM, Ahn S, Barrett CM, Dalton JT, Li W, Miller DD. "Design, synthesis, and biological evaluation of stable colchicine binding site tubulin inhibitors as potential anticancer agents", *J. Med. Chem.* 2014, 57(17):7355-66.

7. Chen J, **Wang J**, Schwab LP, Park KT, Seagroves TN, Jennings LK, Miller DD, Li W. "Benzimidazole analogs as potent hypoxia inducible factor inhibitors: synthesis, biological evaluation, and profiling drug-like properties". *Anticancer Res.* 2014, 34(8):3891-904.

8. **Wang J**, Li W. "Discovery of novel SMAC mimetics as selective IAP inhibitors". *J Pharmacol Exp Ther.*
2014, 349(2):319-29.

9. Chen J, **Wang J**, Kim TK, Tieu EW, Tang E, Lin Z, Kovacic D, Miller DD, Postlethwaite A, Tuckey RC, Slominski AT, Li W. "Novel vitamin D analogs as potential therapeutics: the metabolism, toxicity profiling, and antiproliferative activity". *Anticancer Res.* 2014, 34(5):2153-63.

10. Slominski AT, Kim TK, Shehabi H, Tang E, Benson H, Semak I, Lin Z,Yates C, **Wang J**, Li W, Tuckey RC. "*In vivo* production of novel vitamin D2 hydroxy-derivatives by human placentas, epidermal keratinocytes, Caco-2 colon cells and the adrenal gland". *Mol. Cell Endocrinol*. 2014, 383(1-2):181-92.

11. Slominski AT, Kim TK, Takeda Y, Janjetovic Z, Brozyna A, Skobowiat C, **Wang J**, Postlethwaite A, Li W, Tuckey RC, Jetten A. "RORα and ROR γ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D". *FASEB J*. 2014,
28(7):2775-89.

12. **Wang J**, Chen J, Miller DD, Li W. "Synergistic combination of novel tubulin inhbitor ABI-274 and vemurafenib acquired reistance in $BRAF^{V600E}$ melanoma". *Mol Cancer Ther.* 2014, 13: 16-26.

13. Xiao M, Ahn S, **Wang J**, Chen J, Miller DD, Dalton JT, Li W. "Discovery of 4-Aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties". *J Med Chem.* 2013,
56(8):3318-29.

14. Slominski AT, Janjetovic Z, Tuckey RC, Nguyen MN, Bhattacharya SK, **Wang J**, Li W, Postlethwaite AE. "20S-hydroxyvitamin D3, noncalcemic product of CYP11A1 action on vitamin D3, exhibits potent antifibrotic activity in vivo". *J. Clin. Endocrinol. Metab.* 2013, 98(2):E298-303.

15. **Wang J**, Slominski A, Tuckey RC, Janjetovic Z, Kulkarni A, Chen J, Postlethwaite AE, Miller D, Li W. "20-hydroxyvitamin D3 inhibits proliferation of cancer cells with high efficacy while being non-toxic". *Anticancer Res.* 2012, 32(3):739-46.
16. Kim TK, **Wang J** (equal first author), Janjetovic Z, Chen J, Tuckey RC, Nguyen MN, Tang EK, Miller D, Li W, Slominski AT. "Correlation between secosteroid-induced vitamin D receptor activity in melanoma cells and computer-modeled receptor binding strength". *Mol. Cell Endocrinol*. 2012, 361(1-2):143-52.

17. Patil SA, **Wang J**, Li XS, Chen J, Jones TS, Hosni-Ahmed A, Patil R, Seibel WL, Li W, Miller DD. "New substituted 4H-chromenes as anticancer agents". *Bioorg Med Chem Lett.* 2012, 22(13):4458-61.

18. Chen J, Ahn S, **Wang J**, Lu Y, Dalton JT, Miller DD, Li W. "Discovery of novel 2-aryl-4-benzoyl- imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents". *J Med Chem.* 2012, 55(16):7285-9.

19. Wang Z, Chen J, **Wang J**, Ahn S, Li CM, Lu Y, Loveless VS, Dalton JT, Miller DD, Li W. "Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis". *Pharm Res*. 2012, 29(11):3040-52.

20. Chen J, Li CM, **Wang J**, Ahn S, Wang Z, Lu Y, Dalton JT, Miller DD, Li W. "Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization". *Bioorg Med Chem*. 2011, 19(16):4782-95.

21. Lu Y, Chen J, Janjetovic Z, Michaels P, Tang EK, **Wang J**, Tuckey RC, Slominski AT, Li W, Miller DD. "Design, synthesis, and biological action of 20R-hydroxyvitamin D3". *J Med Chem*. 2012, 55(7):3573-7.

22. Pan X, Chen M, Han K, Peng X, Wen X, Chen B, **Wang J**, Li G, Wu C. "Novel compaction techniques with pellet-containing granules". *Eur J Pharm Biopharm.* 2010, 75(3):436-42.

BOOK CHAPTER

Wang J, Miller DD, Li W. "Emerging Drug Combination Approaches in Melanoma Therapy", Melanoma, ISBN 978-953-51-4133-4, InTech, 2014 Sep

ISSUED PATENTS

Wang J, Chen J, Miller DD, Li W. "Compounds for treatment of cancer", US 8,822,513 B2, issued on 9/2/2014.
Li W, Xiao M, Dalton J, Ahn S, Miller DD, Chen J, **Wang J.** "Compounds for treatment of cancer" US 9,029,408 B2, issued on 5/12/2015

PUBLISHED CONFERENCE ABSTRACTS

1. Lu Y, Li CM, Wang Z, **Wang J**, Chen J, Li W. Dalton JT, Miller DD. "Synthesis and SAR studies of colchicine binding site tubulin inhibitors as potent and orally bioavailable anticancer agents", 242nd ACS National Meeting Denver, Colorado, August 28 - September 1, 2011.

2. **Wang J**, Slominski A, Tuckey R, Janjetovic Z, Kulkarni A, Chen J, Postlethwaite AE, Miller DD, Li W. "20- Hydroxylvitamin D3 possesses high efficacy against proliferation of cancer cells while being non-toxic", 2012
SID Annual Meeting & 75th Anniversary Celebration, Raleigh Convention Center Raleigh, North Carolina, May 9 - 12, 2012.

3. Patil SA, Jones TS, Hosni-Ahmed A, **Wang J**, Patil R, Li W and Miller DD. "New substituted 4H-chromenes as antiglioma agents", 244th American Chemistry Society National Meeting & Exposition, Philadelphia, Pennsylvania, August 19-23, 2012.

4. Lu Y, **Wang J**, Li W, Miller DD. "Effects of selective androgen-receptor and estrogen receptor modulators on telomerase activity in melanoma and prostate cancer cells", 2013 AACR annual meeting, Washington, DC, April 6-10, 2013.

5. **Wang J**, Duke CB, Li W. "Identify novel molecular structures targeting X-linked inhibitor of apoptosis protein by ligand-based virtual screening", 2013 AACR annual meeting, Washington, DC, April 6-10, 2013.

6. Li W, Chen J, Lu Y, **Wang J**, Tang KY, Slominski AT, Tuckey R, Postlethwaite AE, Miller DD. "Design, synthesis and biological evaluation of novel non-calcemic vitamin D receptor modulators", 2nd Congress on Steroid Research, Chicago, March 10-12, 2013.

7. **Wang J**, Chen J, Miller DD, Li W. "Overcoming acquired resistance to Braf inhibitors by a novel synergistic drug combination", 18th annual Pan American Society for Pigment Cell Research meeting, September 8-11, 2013, Madison, Wisconsin.

8. **Wang J** and Li W. "Discovery of novel SMAC mimetics as selective IAP inhibitors", 2014 AACR annual meeting, San Diego, April 5-10, 2014.

9. Slominski AT, Kim TK, Takeda Y, Janjetovic Z, Brozyna A, Skobowiat C, **Wang J**, Postlethwaite AE, Li W, Tuckey RC, Jetten A. "RORα and ROR γ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy and 20,23-dihydroxy-vitamin D", International Society of Endocrinology and The Endocrine Society: ICE/ENDO 2014, Chicago, June 21-24, 2014.

10. Slominski AT, Kim TK, Janjetovic Z, Lin Z, Chen J, **Wang J**, Tuckey RC, Li W. "Novel noncalcemic secosteroids are produced in the human epidermis and protect against solar radiation", International Society of Endocrinology and The Endocrine Society: ICE/ENDO 2014, Chicago, June 21-24, 2014.

11. Xiao M, **Wang J**, Lu Y, Miller DD, Li W, "Design, synthesis and SAR studies of novel survivin inhibitors with potent anti-proliferative properties", 248th ACS National Meeting & Exposition, San Francisco, CA, August 10-14, 2014.

12. Xiao M, **Wang J**, Lu Y, Miller DD, Li W. "Target validation and structural optimization of selective small molecule survivin inhibitors as potential anti-cancer agents". 2015 AACR annual meeting, Philiadelphia, April 18-22, 2015.